CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company employing its proprietary transformer base editing (tBE) technology to pioneer next-generation gene editing therapies.
Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrates its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies.
Proof-of-concept (POC) data in mice for in vivo pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases.
Ex vivo multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function in vivo compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development.
tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs or adeno-associated viruses (AAVs).
We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.
Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.
Company Details
- Employees
- 9
- Founded
- -
- Address
- No.99, Haike Road, Pudong Distrct, Shanghai,shanghai 200120,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.correctsequence.com/
- Keywords
- 성남시.
- HQ
- Shanghai, Shanghai
Correctsequence Therapeutics Questions
Correctsequence Therapeutics's website is https://www.correctsequence.com/
Correctsequence Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/correctsequence-therapeutics
Correctsequence Therapeutics has
9 employees.
View email and phone details for 9
employees at Correctsequence Therapeutics.
Correctsequence Therapeutics's industry is
Biotechnology Research
Correctsequence Therapeutics's top competitors are
Obio,
Rznomics Inc.,
Obio Tech,
Crispr Therapeutics,
Ascidian Therapeutics,
Profoundbio,
Ifpma,
Vyriad,
Passage Bio,
Yoltech Therapeutics.
Correctsequence Therapeutics's categories are Biotechnology Research
Correctsequence Therapeutics's founding year is 2020
